Background: Pulmonary arterial hypertension (PAH) is a refractory disease. Its prognosis remains poor; hence, establishment of novel therapeutic targets is urgent. TP53-induced glycolysis and apoptosis regulator (TIGAR) is a downstream target of p53, and exhibits functions inhibiting autophagy and reactive oxygen species (ROS). Recently, p53 was shown to suppress the PAH progression. Since inhibition of autophagy and ROS are known to improve PAH, we examined the effect of TIGAR on PAH progression. Methods: We compared pulmonary hypertension (PH) development between TIGAR-deficient knockout (KO) and wild type (WT) mice using a hypoxia-induced PH model. Human pulmonary artery smooth muscle cells (PASMCs) were used for in vitro experiments with small interfering RNA (siRNA) to investigate the possible molecular mechanisms. Results: From analysis of right ventricular pressure, right heart weight, and mortality rate, we concluded that the hypoxia-induced PH development was remarkably higher in TIGAR KO than in the WT mice. Pathological investigation revealed that medial thickening of the pulmonary arterioles and cell proliferation was increased in TIGAR KO mice. Autophagy and ROS activity was also increased in TIGAR KO mice. TIGAR knockdown by siRNA increased cell proliferation and migration, exacerbated autophagy, and increased ROS generation during hypoxia. Autophagy inhibition by chloroquine and ROS inhibition by N-acetylcysteine attenuated the proliferation and migration of PASMCs caused by TIGAR knockdown and hypoxia exposure. Conclusions: TIGAR suppressed the proliferation and migration of PASMCs via inhibiting autophagy and ROS, and therefore, improved hypoxia-induced PH. Thus, TIGAR might be a promising therapeutic target for PAH.
Nonalcoholic steatohepatitis (NASH) is a progressive disorder with aberrant lipid accumulation and subsequent inflammatory and profibrotic response. Therapeutic efforts at lipid reduction via increasing cytoplasmic lipolysis unfortunately worsens hepatitis due to toxicity of liberated fatty acid. An alternative approach could be lipid reduction through autophagic disposal, i.e., lipophagy. We engineered a synthetic adaptor protein to induce lipophagy, combining a lipid droplet-targeting signal with optimized LC3-interacting domain. Activating hepatocyte lipophagy in vivo strongly mitigated both steatosis and hepatitis in a diet-induced mouse NASH model. Mechanistically, activated lipophagy promoted the excretion of lipid from hepatocytes via lysosomal exocytosis, thereby suppressing harmful intracellular accumulation of nonesterified fatty acid. A high-content compound screen identified alpelisib and digoxin, clinically-approved compounds, as effective activators of lipophagy. Administration of alpelisib or digoxin in vivo strongly inhibited the transition to steatohepatitis. These data thus identify lipophagy as a promising therapeutic approach to prevent NASH progression.
The findings of this study show that meibomian glands exhibit a cyclic change in premenopausal women, as well as sex- and age-related physiologic differences.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.